Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila Shapouri

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Advances in Therapy|May 6, 2024
Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims AnalysisElmor D Pineda, Tu My To, Travis L Dickendesher, et al.
Pharmacoeconomics|February 1, 2024
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USAShih-Wen Lin, Sheila Shapouri, Hélène Parisé, et al.
Oncology (Williston Park, N.Y.)|January 28, 2022
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabEsther Drill, Annie Qiu, Sheila Shapouri, et al.
Journal of Medical Economics|May 7, 2024
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United StatesMatthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Cost Effectiveness and Resource Allocation : C/E|August 23, 2023
Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocolAbigail G Riley, Christina M Mulé, Debra Lerner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2025
Author ReplyTara A Lavelle, Sheila Shapouri, Abigail Riley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2025
Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular AtrophyTara A Lavelle, Abigail Riley, Stacey Kowal, et al.
Pharmacoeconomics|May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
Journal of Pain and Symptom Management|September 24, 2025
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1Christina M Mulé, Abigail Riley, Debra Lerner, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Advances in Therapy|May 6, 2024
Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims AnalysisElmor D Pineda, Tu My To, Travis L Dickendesher, et al.
Pharmacoeconomics|February 1, 2024
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USAShih-Wen Lin, Sheila Shapouri, Hélène Parisé, et al.
Oncology (Williston Park, N.Y.)|January 28, 2022
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabEsther Drill, Annie Qiu, Sheila Shapouri, et al.
Journal of Medical Economics|May 7, 2024
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United StatesMatthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Sheila Shapouri, Beenish S Manzoor, et al.
Cost Effectiveness and Resource Allocation : C/E|August 23, 2023
Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocolAbigail G Riley, Christina M Mulé, Debra Lerner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2025
Author ReplyTara A Lavelle, Sheila Shapouri, Abigail Riley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2025
Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular AtrophyTara A Lavelle, Abigail Riley, Stacey Kowal, et al.
Pharmacoeconomics|May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
Journal of Pain and Symptom Management|September 24, 2025
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1Christina M Mulé, Abigail Riley, Debra Lerner, et al.
Pageof 2